Browse recruiting and upcoming clinical trials for autoimmune hemolytic anemia.
Patient-friendly, AI-assisted summaries based on official ClinicalTrials.gov ↗ records. Last updated: Oct 10, 2026
About this listHide
ClinicalTrials.gov is the complete and most up-to-date source. Trials may be missing, and trial information may have changed since our last check. Always verify important information in the official registry.
Who can join AIAdults 18–60 with relapsed/refractory systemic lupus erythematosus (SLE) or refractory autoimmune hemolytic anemia (AIHA/Evans syndrome).
What is being studied AITests safety, pharmacokinetics, and pharmacodynamics of Arnovie101 in B cell–mediated autoimmune disease.
Who can join AIAdults with relapsed/refractory primary Immune Thrombocytopenia (ITP) or relapsed/refractory primary Warm Autoimmune Hemolytic Anemia (wAIHA).
What is being studied AITests safety, preliminary efficacy, and blood effects of CTX112 (anti‑CD19 CAR T cell therapy)
Who can join AIPeople aged ≥10 with autoimmune hemolytic anemia (warm, cold, mixed, or other types) who are CD19- or BCMA-positive and have failed ≥3 prior therapies.
What is being studied AITests one intravenous infusion of universal allogeneic anti‑CD19/BCMA CAR T‑cells.
Who can join AIAdults (18–85) with relapsed or refractory autoimmune hemolytic anemia (warm or cold), including Evans syndrome and some secondary cases.
What is being studied AITests oral orelabrutinib at different doses for response and safety in relapsed/refractory AIHA.
Who can join AIAdults 18–70 with relapsed or refractory systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathies, Sjögren's syndrome, autoimmune hemolytic anemia, or multiple sclerosis.
What is being studied AITests safety and effects of a dual-target CD19-BCMA CAR-T cell therapy.
Who can join AIAdults 18–75 with relapsed/refractory B-cell malignancies (B-ALL, CLL, B-NHL) that are CD19-positive, or people with autoimmune hemolytic anemia (AIHA).
What is being studied AITests safety and efficacy of GT801 injection in adults with relapsed/refractory CD19-positive B‑cell diseases and AIHA.
Who can join AIAdults (18–100) with Primary ITP or warm autoimmune hemolytic anemia (wAIHA; primary or secondary) who previously benefited from ianalumab in parent trials and meet relapse/failure rules.
What is being studied AITests a second course of ianalumab in adults who previously benefited from ianalumab.
Who can join AIAdults (≥18) with autoimmune hemolytic anemia (warm, cold, mixed, or other types) who have failed ≥3 lines of therapy and have CD19‑ or BCMA‑positive B cells.
What is being studied AITests a single infusion of universal allogeneic anti-CD19/BCMA CAR T-cells for AIHA.
Who can join AIAdults (≥18) with primary warm autoimmune hemolytic anemia whose disease is steroid-refractory, steroid‑intolerant, or who refuse standard steroid treatment.
What is being studied AICompares cyclosporine with rituximab as second-line drug treatments for primary AIHA.
Who can join AIAdults (18–75) with relapsed or refractory warm‑antibody autoimmune hemolytic anemia (wAIHA) who meet the study's other entry requirements.
What is being studied AITests safety, pharmacokinetics, and activity of CD19/BCMA CAR‑T therapy in relapsed/refractory wAIHA.
Who can join AIAdults (≥18) with autoimmune hemolytic anemia (including Evans Syndrome and warm, mixed, or cold types) who have failed ≥3 lines of therapy.
What is being studied AITests safety, tolerability, early efficacy, and PK/PD of YTS109 cell therapy in refractory AIHA.
Who can join AIAdults (18–75) with primary warm‑antibody autoimmune hemolytic anemia (wAIHA) that has relapsed or is refractory after at least second‑line treatment.
What is being studied AITests enatumab (BCMA/CD3 bispecific antibody) given subcutaneously for relapsed/refractory warm AIHA.
Who can join AIAdults 18–75 with autoimmune hemolytic anemia (warm, mixed, Evans syndrome, or cold/CAD) who have failed at least three prior lines of therapy.
What is being studied AITests safety, tolerability, and dose of Inaticabtagene autoleucel CAR‑T in autoimmune hemolytic anemia.
Who can join AIAdults (18 years or older) with relapsed or refractory autoimmune diseases including SLE, AIHA, myasthenia gravis, systemic sclerosis, AAV, inflammatory myopathy, or IgG4‑RD.
What is being studied AITests a single infusion of universal allogeneic CAR T-cells targeting CD19 and BCMA.
Who can join AIAdults (≥18) with warm or cold autoimmune hemolytic anemia (primary or certain secondary autoimmune causes) who are refractory or relapsed after steroids.
What is being studied AITests iptacopan as a treatment for refractory or relapsed autoimmune hemolytic anemia.
Who can join AIPeople diagnosed with autoimmune hemolytic anemia (warm, cold, or mixed) with hemoglobin <100 g/L treated at the Institute of Hematology and Blood Diseases Hospital from Jan 1, 2001.
What is being studied AICollects clinical, treatment, outcome, and cost data on people diagnosed with autoimmune hemolytic anemia.
Who can join AIPeople diagnosed with certain hematological (blood) diseases or who received a bone marrow transplant at a participating hospital on or after January 1, 2020.
What is being studied AICollects clinical, treatment, outcome, and cost data for people with hematological diseases.
Who can join AIAdults 18–75 with relapsed or refractory autoimmune hemolytic anemia — including wAIHA, cAIHA, Evans syndrome, or AIHA with connective-tissue disease.
What is being studied AICollects response and adverse-event data during 12 weeks of linprixel/parsaclisib treatment.
Trials that may include autoimmune hemolytic anemia (2)
ClinicalTrials.gov returned these when we searched for this condition, but we could not confirm from the registry records that they are intended for people with it. Check each trial’s eligibility criteria, and ask the study team if you are unsure.